David L. Johnson
Directeur/Membre du Conseil chez Energy Systems Network
Profil
David L.
Johnson is currently the Director at Energy Systems Network.
He previously held positions as President & Chief Executive Officer at The Central Indiana Corporate Partnership and BioCrossroads.
He also served as Director at CS-Keys, Inc. and Bioscience Vaccines, Inc. Johnson received his undergraduate degrees from Harvard University in 1974 and the University of Oxford in 1976.
Postes actifs de David L. Johnson
| Sociétés | Poste | Début |
|---|---|---|
Energy Systems Network
 Energy Systems Network Packaged SoftwareTechnology Services Energy Systems Network (ESN) is a non-profit organization founded in 2009 that works with companies worldwide to accelerate the development and commercialization of energy and transportation technology. ESN is based in Indianapolis, IN, and is part of the Central Indiana Corporate Partnership (CICP). ESN conducts industry research, pilot projects, and collaborative convening to advance new technologies and solutions. The organization has worked with companies such as Cummins, Duke Energy, Delphi, Toyota, and Toshiba, among others, to showcase and advance new technologies. The CEO of ESN is Paul Mitchell. | Directeur/Membre du Conseil | - |
Anciens postes connus de David L. Johnson
| Sociétés | Poste | Fin |
|---|---|---|
The Central Indiana Corporate Partnership
 The Central Indiana Corporate Partnership Miscellaneous Commercial ServicesCommercial Services The Central Indiana Corporate Partnership is a private company that focuses on human capital, entrepreneurship, innovation, and business climate. The company is based in Indianapolis, IN and has subsidiaries in the United States. The CEO of the company is Melina M. Kennedy. | Directeur Général | 31/12/2022 |
BioCrossroads
 BioCrossroads Investment ManagersFinance BioCrossroads (BioCrossroads) is a venture capital firm founded in 2002. The firm is headquartered in Indianapolis, Indiana. | Directeur Général | 31/12/2018 |
Bioscience Vaccines, Inc.
 Bioscience Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Bioscience Vaccines, Inc. develops a novel technology for the development of vaccine supplements. It engages in development of a vaccine adjuvant and companion products for infectious diseases. The firm also involves in the exploration of prevention and immunotherapeutic treatments for cancer using tissue vaccines. The company was founded by Anthony J. Hubbard and and Amy M. Overby in 2010 and is headquartered in West Lafayette, IN. | Directeur/Membre du Conseil | - |
CS-Keys, Inc.
 CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University. | Directeur/Membre du Conseil | - |
Formation de David L. Johnson
| Harvard University | Undergraduate Degree |
| University of Oxford | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
CS-Keys, Inc.
CS-Keys, Inc. Medical SpecialtiesHealth Technology CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University. | Health Technology |
The Central Indiana Corporate Partnership
The Central Indiana Corporate Partnership Miscellaneous Commercial ServicesCommercial Services The Central Indiana Corporate Partnership is a private company that focuses on human capital, entrepreneurship, innovation, and business climate. The company is based in Indianapolis, IN and has subsidiaries in the United States. The CEO of the company is Melina M. Kennedy. | Commercial Services |
BioCrossroads
BioCrossroads Investment ManagersFinance BioCrossroads (BioCrossroads) is a venture capital firm founded in 2002. The firm is headquartered in Indianapolis, Indiana. | Finance |
Energy Systems Network
Energy Systems Network Packaged SoftwareTechnology Services Energy Systems Network (ESN) is a non-profit organization founded in 2009 that works with companies worldwide to accelerate the development and commercialization of energy and transportation technology. ESN is based in Indianapolis, IN, and is part of the Central Indiana Corporate Partnership (CICP). ESN conducts industry research, pilot projects, and collaborative convening to advance new technologies and solutions. The organization has worked with companies such as Cummins, Duke Energy, Delphi, Toyota, and Toshiba, among others, to showcase and advance new technologies. The CEO of ESN is Paul Mitchell. | Technology Services |
Bioscience Vaccines, Inc.
Bioscience Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Bioscience Vaccines, Inc. develops a novel technology for the development of vaccine supplements. It engages in development of a vaccine adjuvant and companion products for infectious diseases. The firm also involves in the exploration of prevention and immunotherapeutic treatments for cancer using tissue vaccines. The company was founded by Anthony J. Hubbard and and Amy M. Overby in 2010 and is headquartered in West Lafayette, IN. | Health Technology |